Journal article icon

Journal article

A systematic analysis of the human immune response to Plasmodium vivax

Abstract:

Background. The biology of Plasmodium vivax is markedly different from that of P. falciparum; how this shapes the immune response to infection remains unclear. To address this shortfall, we inoculated human volunteers with a clonal field isolate of P. vivax and tracked their response through infection and convalescence.

Methods. Participants were injected intravenously with blood-stage parasites and infection dynamics were tracked in real time by quantitative PCR. Whole blood samples were used for high dimensional protein analysis, RNA sequencing, and cytometry by time of flight, and temporal changes in the host response to P. vivax were quantified by linear regression. Comparative analyses with P. falciparum were then undertaken using analogous data sets derived from prior controlled human malaria infection studies.

Results. P. vivax rapidly induced a type I inflammatory response that coincided with hallmark features of clinical malaria. This acute-phase response shared remarkable overlap with that induced by P. falciparum but was significantly elevated (at RNA and protein levels), leading to an increased incidence of pyrexia. In contrast, T cell activation and terminal differentiation were significantly increased in volunteers infected with P. falciparum. Heterogeneous CD4+ T cells were found to dominate this adaptive response and phenotypic analysis revealed unexpected features normally associated with cytotoxicity and autoinflammatory disease.

Conclusion. P. vivax triggers increased systemic interferon signaling (cf P. falciparum), which likely explains its reduced pyrogenic threshold. In contrast, P. falciparum drives T cell activation far in excess of P. vivax, which may partially explain why falciparum malaria more frequently causes severe disease.

Trial registration. ClinicalTrials.gov NCT03797989.

Funding. The European Union’s Horizon 2020 Research and Innovation programme, the Wellcome Trust, and the Royal Society.

Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Files:
Publisher copy:
10.1172/jci152463

Authors

More by this author
Role:
Author
ORCID:
0000-0002-0126-5516
More by this author
Role:
Author
ORCID:
0000-0001-8350-3989
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDM
Sub department:
Jenner Institute
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDM
Sub department:
Jenner Institute
Role:
Author



Publisher:
American Society for Clinical Investigation
Journal:
Journal of Clinical Investigation More from this journal
Volume:
133
Issue:
20
Article number:
e152463
Place of publication:
United States
Publication date:
2023-10-16
Acceptance date:
2023-08-22
DOI:
EISSN:
1558-8238
ISSN:
0021-9738
Pmid:
37616070


Language:
English
Pubs id:
1518135
Local pid:
pubs:1518135
Deposit date:
2023-10-25
ARK identifier:

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP